Global Blood Therapeutics – $144 Million Shelf‑Takedown

San Diego – March 8, 2017 – Cooley advised the underwriters on Global Blood Therapeutics’ $143.8 million shelf-takedown offering of 5,867,347 shares of common stock, which includes the full exercise of the underwriters’ option to purchase up to 765,306 additional shares of common stock.

Cantor Fitzgerald & Co. acted as sole book-running manager for the offering.

Global Blood Therapeutics, which trades on The NASDAQ Global Select Market as “GBT,” is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat blood-based disorders with significant unmet need.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Charlie Kim Partner, San Diego
Div Gupta Partner, New York
Robert Phillips Partner, San Francisco
Kristin VanderPas Partner, San Francisco
Denny Won Associate, San Diego
Sunny Chang Associate, San Diego
Denise Stark Paralegal Specialist, San Diego
Heidi Ausman Senior Paralegal, San Diego
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Bill Christiansen Partner, Seattle
Aaron Nudelman Associate, Seattle
Kevin King Partner, Washington, DC
Karen Tsai Associate, Washington, DC
Susan Cooper Philpot Partner, San Francisco
Darren DeStefano Partner, Reston